| The SkinJect Value Proposition
1. Innovative Microneedle Patch Technology:
- The company aims to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting.
- Patented technology for non-invasively treating skin cancer using cellulose-based microneedles to deliver cancer drugs directly to the tumor site
- Exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016.
2. Market Potential:
- BCC is the most common and fastest-growing cancer globally.
- >US$15Bn market for skin cancer treatments in North America by 2030. (1)
- Potential for further market expansion and penetration by SkinJect’s novel treatment approach.
3. Positive Clinical Trial Results:
- Phase 1 trial completed March 2021, demonstrating safety and tolerability.
- In Q1 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study.
- In Q3 2024 Phase 2 enrollment began.
- In Q1 2025 conducted interim analysis after 50% patient recruitment.
- In Q2 2025, IRB approved to increase number of patients from 60 to 90.
4. Seasoned Leadership and Board:
- Management team with public company experience.
- Board includes industry veterans and experts in oncology and drug development.
Grab Key Sources: MDCX Presentation. MDCX Website. -----
And as I mentioned previously, (Nasdaq: MDCX) has several potential catalysts that could generate breakout buzz. Check them out:
No. 1 MDCX Potential Catalyst - A Low Float Could Create The Environment For Heightened Volatility.
According to info from the Finviz website, MDCX has a fairly low float.
The website reports this profile to have roughly 2.34Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears in the midway part of 2025, could it provide a breakout spark? -----
No. 2 MDCX Potential Catalyst - A Definitive Agreement Moves Medicus Pharma A Step Closer To A Game-Changing Acquisition.
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65Mn in Contingent Payments
Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced today that they have entered into a definitive agreement dated June 29, 2025 (the "Definitive Agreement") pursuant to which Medicus has agreed to acquire all of the issued and outstanding shares of Antev (the "Antev Shares") on a share exchange basis (the "Transaction").
Subject to the closing conditions noted in the Definitive Agreement, Medicus will acquire all issued and outstanding Antev Shares, on a fully diluted basis, in exchange for 2,666,600 (or approximately 17% in aggregate) of the issued and outstanding Medicus common shares (the "Consideration Shares").
...
The Transaction is expected to close before the end of August 2025, subject to the fulfillment of certain closing conditions, including obtaining Antev shareholder approval and other applicable corporate, regulatory and third-party approvals. No assurances can be given that the parties will successfully close the Transaction on the terms or timeframe currently contemplated or at all.
Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate.
Antev Acute Urinary Retention (AUR) Indication:
Teverelix is aiming to be the first-in-class indication product for preventing recurrence of acute urinary retention (AURr) in males 45 years or older, who suffer from prostate enlargement. Antev has a US Food and Drug Administration (FDA) approved phase 2b study designed to randomize 390 men after a successful trial without catheterization (TWOC). 85% of nearly one million (1M) annual AUR episodes in the US occur in Men 60+ who suffer from enlarged prostate that manifests with age and frequently is followed by a recurrent episode within 6 months for approximately 30% of men, presenting a potential market opportunity of more than US $2Bn annually.
Antev planned Phase 2b Study Design in Acute Urinary Retention:
Randomized controlled double blinded study in 390 men after a successful TWOC in 60-70 sites in United States (US) and European Union (EU). The participants shall receive either single intramuscular (IM) or subcutaneous (SC) injection (90mg or 120mg) or placebo in addition to standard therapy. Primary endpoint is a composite of AURr, need for surgery or poor urinary flow metrics in the first 28 weeks plus 24 weeks follow up.
Antev High Cardiovascular (CV) Risk Advanced Prostate Cancer (APC) indication:
Teverelix is aiming to be the best-in-class indication product for hormone therapy for advanced prostate cancer (APC) patients with increased CV risk. Antev has a US Food and Drug Administration (FDA) approved phase 2b open label study designed to recruit 40 men with advanced prostate cancer. Antev is targeting a niche in patients with increased CV risk, aiming to provide an androgen deprivation therapy (ADT) option with potentially lower cardiac toxicity than conventional GnRH agonists. If approved, Teverelix could become the first hormone therapy labeled specifically for treating prostate cancer in patients with a history of cardiovascular disease. 300,000 to 500,000 men in the US are living with advanced stage prostate cancer presenting a potential market opportunity of more than US $4Bn annually.
Antev planned Phase 2b Study Design in Advanced Prostate Cancer
Open label study in 40 men with advanced prostate cancer suitable for ADT. The participants shall receive a loading dose of 180mg IM plus x2 180mg SC (total 540mg), followed by x2 180mg (360mg) SC day 29 and every 6 weeks. The total duration of the treatment is 22 weeks. Primary endpoint is to confirm castration rate by day 29, sustaining to day 155, probability greater than 90%.
...
Read the full article here. -----
No. 3 MDCX Potential Catalyst - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!).
Check out what MarketBeat is reporting: | 
No comments:
Post a Comment